Is metronidazole teratogenic? A meta-analysis
Is metronidazole teratogenic? A meta-analysis
复制标题
DOI：
10.1046/j.1365-2125.1997.00660.x
复制
发表时间：
1997-08-01
影响因子：
3.4
通讯作者：
Pinilla, ER
中科院分区：
文献类型：
--
作者：
CaroPaton, T;Carvajal, A;Pinilla, ER
目的为了评估是否使用甲硝唑在怀孕期间是与先天性畸形的风险较高，荟萃分析centered.Methods所有流行病学研究（队列和病例对照）估计先天性畸形的风险暴露后，甲硝唑在妊娠早期被纳入荟萃分析。使用Mantel-Haenszel方法获得汇总比值比。一个测试，以验证没有异质性也performed.Results未发表的病例对照，和4个发表的队列研究符合纳入标准，并没有统计异质性。计算妊娠早期甲硝唑暴露的总体比值比：OR = 1.08，95% CI：0.90-1.29，异质性检验χ 2 = 4.72，P = 0.32。结论妊娠早期甲硝唑暴露与出生缺陷无相关性。
Aim In order to assess whether the use of metronidazole during pregnancy is associated with a higher risk of congenital malformations, a meta-analysis was conducted.Methods All epidemiological studies (cohort and case-control) which estimate risk of congenital malformations after exposure to metronidazole during early pregnancy were included in the meta-analysis. To obtain a summary odds ratio, the Mantel-Haenszel method was used. A test to verify absence of heterogeneity was also performed.Results One unpublished case-control, and four published cohort studies fulfilled the inclusion criteria and were not statistically heterogeneous. A summary odds ratio was calculated for metronidazole exposure during the first trimester: OR = 1.08, 95% CI: 0.90-1.29, heterogeneity test chi(2) = 4.72, P = 0.32.Conclusions This meta-analysis did not find any relationship between metronidazole exposure during the first trimester of pregnancy and birth defects.